Merck Announces Presentation of Phase 3 Results of Investigational Elbasvir/Grazoprevir in People with Chronic Hepatitis C Genotypes 1, 4 or 6 Infection Who Inject Drugs and Are on Opioid Agonist Therapy
November 15, 2015 at 09:55 AM EST
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of results ...